Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours a pilot study (IONIC-1)

Next Previous
Trial Profile

Safety and Efficacy of NOX66 in combination with Nivolumab for patients with solid tumours a pilot study (IONIC-1)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idronoxil (Primary) ; Nivolumab (Primary)
  • Indications Gastric cancer; Lung cancer; Nasopharyngeal cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms IONIC-1
  • Sponsors Noxopharm

Most Recent Events

  • 06 Jun 2023 Results (n=11) assessing the safety and preliminary efficacy of NOX66 in combination with nivolumab in patients with advanced cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 24 Apr 2023 According to a Noxopharm media release, this trial is taking place at six sites in the Sydney area and regional NSW. The current patient cohort is being treated with a Veyonda dose of 1800mg, however the slow recruitment rate remains a challenge. Preliminary data from the IONIC trial will be published online in conjunction with the upcoming American Society of Clinical Oncology (ASCO) annual meeting taking place from 2-6 June 2023.
  • 11 Nov 2021 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top